AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2021
Feb 26, 2021
29864_dirs_2021-02-26_f37b68cf-3bca-4335-a79a-fe781148107a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2021-02-24
Reporting Person: Sachdev Amit (EVP, Chief Patient Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-24 | Common Stock | F | 2946 | $217.57 | Disposed | 43719 | Direct |
| 2021-02-25 | Common Stock | S | 922 | $211.56 | Disposed | 42797 | Direct |
| 2021-02-25 | Common Stock | S | 1460 | $213.30 | Disposed | 41337 | Direct |
| 2021-02-25 | Common Stock | S | 668 | $214.19 | Disposed | 40669 | Direct |
| 2021-02-25 | Common Stock | S | 336 | $215.56 | Disposed | 40333 | Direct |
| 2021-02-25 | Common Stock | S | 200 | $216.62 | Disposed | 40133 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 882 | Indirect |
| Common Stock | 7368 | Indirect |
Footnotes
F1: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $211.56 (range $211.06 to $211.87).
F3: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $213.30 (range $212.93 to $213.88).
F5: Open market sales reported on this line occurred at a weighted average price of $214.19 (range $213.94 to $214.78).
F6: Open market sales reported on this line occurred at a weighted average price of $215.56 (range $215.12 to $215.85).